To include your compound in the COVID-19 Resource Center, submit it here.

EntreMed, Allergan, Oculex deal

Under a 5-year deal, the companies will develop and commercialize small molecule angiogenesis inhibitors

Read the full 140 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE